BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL; Short‐Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short‐Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost‐Effectiveness Analysis Based on a Multicenter Clinical Trial. CLIN INFECT DIS 2004;38:363-9. [DOI: 10.1086/380966] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Patel AR, Campbell JR, Sadatsafavi M, Marra F, Johnston JC, Smillie K, Lester RT. Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. BMJ Open 2017;7:e015108. [PMID: 28918407 DOI: 10.1136/bmjopen-2016-015108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
2 Trauer JM, Moyo N, Tay EL, Dale K, Ragonnet R, McBryde ES, Denholm JT. Risk of Active Tuberculosis in the Five Years Following Infection . . . 15%? Chest 2016;149:516-25. [PMID: 26867835 DOI: 10.1016/j.chest.2015.11.017] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 8.9] [Reference Citation Analysis]
3 Chang X, Xu Y, Liu C. A rapid and sensitive colorimetric measurement of antibiotic efficacy against Escherichia coli in vitro. FEMS Microbiol Lett 2016;363:fnw037. [PMID: 26892018 DOI: 10.1093/femsle/fnw037] [Reference Citation Analysis]
4 Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014;190:1044-52. [PMID: 25265362 DOI: 10.1164/rccm.201406-1159OC] [Cited by in Crossref: 124] [Cited by in F6Publishing: 132] [Article Influence: 13.8] [Reference Citation Analysis]
5 Zhanel GG, Wolter KD, Calciu C, Hogan P, Low DE, Weiss K, Karlowsky JA. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. J Antimicrob Chemother 2014;69:2835-40. [PMID: 24920652 DOI: 10.1093/jac/dku207] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
6 Chavan S, Newlands D, Smith C. A systematic review of economic evaluations of chemoprophylaxis for tuberculosis. J Trop Med 2011;2011:130976. [PMID: 22131996 DOI: 10.1155/2011/130976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
7 Holland DP, Sanders GD, Hamilton CD, Stout JE. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One 2011;6:e22276. [PMID: 21789248 DOI: 10.1371/journal.pone.0022276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
8 Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update: Treatment of latent TB infection. Respirology 2010;15:603-22. [DOI: 10.1111/j.1440-1843.2010.01751.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 10.3] [Reference Citation Analysis]
9 Caminero JA. ¿Podemos mejorar la prevención de la tuberculosis? Enfermedades Infecciosas y Microbiología Clínica 2010;28:211-214. [DOI: 10.1016/j.eimc.2009.12.004] [Reference Citation Analysis]
10 Sánchez F, Balagué M, García de Olalla P, López Colomés JL, Martín V, Guerrero R, Marco A, Caylà JA. Treatment of latent Mycobacterium tuberculosis infection in intravenous drug users co-infected with HIV. Journal of Infection Prevention 2010;11:12-8. [DOI: 10.1177/1757177409354732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Pisu M, Gerald J, Shamiyeh JE, Bailey WC, Gerald LB. Targeted tuberculosis contact investigation saves money without sacrificing health. J Public Health Manag Pract 2009;15:319-27. [PMID: 19525776 DOI: 10.1097/PHH.0b013e31819c3ef2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Nelson CL, Sun JL, Tsiatis AA, Mark DB. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology. Stat Med 2008;27:5525-55. [PMID: 18613251 DOI: 10.1002/sim.3355] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
13 Alma MG, Altieri AM. Tubercolosi polmonare. Malattie dell’apparato respiratorio. [DOI: 10.1007/978-88-470-0467-2_22] [Reference Citation Analysis]
14 Kominski GF, Varon SF, Morisky DE, Malotte CK, Ebin VJ, Coly A, Chiao C. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health 2007;40:61-8. [PMID: 17185207 DOI: 10.1016/j.jadohealth.2006.08.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
15 Peterson LR. Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter? Clinical Infectious Diseases 2006;42:224-33. [DOI: 10.1086/497594] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 3.9] [Reference Citation Analysis]
16 Pagnoux C, Guillevin L. How can patient care be improved beyond medical treatment? Best Practice & Research Clinical Rheumatology 2005;19:337-44. [DOI: 10.1016/j.berh.2004.11.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
17 Barie PS, Rotstein OD, Dellinger EP, Grasela TH, Walawander CA. The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection. Surg Infect (Larchmt) 2004;5:269-80. [PMID: 15684798 DOI: 10.1089/sur.2004.5.269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ijaz K, Mcelroy PD, Navin TR. Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost-Effectiveness Analysis Based on a Multicenter Clinical Trial. Clinical Infectious Diseases 2004;39:289-289. [DOI: 10.1086/421783] [Reference Citation Analysis]